Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries
Background In case of orphan drugs applicability of the standard health technology
assessment (HTA) process is limited due to scarcity of good clinical and health economic …
assessment (HTA) process is limited due to scarcity of good clinical and health economic …
A review of international coverage and pricing strategies for personalized medicine and orphan drugs
I Degtiar - Health Policy, 2017 - Elsevier
Background Personalized medicine and orphan drugs share many characteristics—both
target small patient populations, have uncertainties regarding efficacy and safety at payer …
target small patient populations, have uncertainties regarding efficacy and safety at payer …
Commonalities and differences in HTA outcomes: a comparative analysis of five countries and implications for coverage decisions
OBJECTIVE: To identify diverging HTA recommendations across five countries, understand
the rationale for decision-making in specific therapeutic categories, and suggest ways …
the rationale for decision-making in specific therapeutic categories, and suggest ways …
[HTML][HTML] Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia
KE Fischer, T Heisser, T Stargardt - Health Policy, 2016 - Elsevier
Background Little is known on the performance of the newly introduced health benefit
assessment process, AMNOG, in Germany compared to other health technology …
assessment process, AMNOG, in Germany compared to other health technology …
Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders
M Schlander, S Garattini, S Holm… - Journal of …, 2014 - becarispublishing.com
Drugs for ultra-rare disorders (URDs) rank prominently among the most expensive
medicines on a cost-per-patient basis. Many of them do not meet conventional standards for …
medicines on a cost-per-patient basis. Many of them do not meet conventional standards for …
Shining a light in the black box of orphan drug pricing
E Picavet, T Morel, D Cassiman, S Simoens - Orphanet journal of rare …, 2014 - Springer
Background The pricing mechanism of orphan drugs appears arbitrary and has been
referred to as a “black box”. Therefore, the aim of this study is to investigate how drug-and …
referred to as a “black box”. Therefore, the aim of this study is to investigate how drug-and …
Acceptance of health technology assessment submissions with incremental cost-effectiveness ratios above the cost-effectiveness threshold
EA Griffiths, JK Hendrich, SDR Stoddart… - ClinicoEconomics and …, 2015 - Taylor & Francis
Objectives In health technology assessment (HTA) agencies where cost-effectiveness plays
a role in decision-making, an incremental cost-effectiveness ratio (ICER) threshold is often …
a role in decision-making, an incremental cost-effectiveness ratio (ICER) threshold is often …
[HTML][HTML] Which factors enhance positive drug reimbursement recommendation in Scotland? A retrospective analysis 2006–2013
M Charokopou, IM Majer, J De Raad, S Broekhuizen… - Value in Health, 2015 - Elsevier
Objectives To identify the factors that influence the Scottish Medicines Consortium (SMC) in
deciding whether to accept pharmaceutical technologies for use within the Scottish health …
deciding whether to accept pharmaceutical technologies for use within the Scottish health …
Stated and revealed preferences for funding new high-cost cancer drugs: a critical review of the evidence from patients, the public and payers
Background The growing focus on patient-centred care has encouraged the inclusion of
patient and public input into payer drug reimbursement decisions. Yet, little is known about …
patient and public input into payer drug reimbursement decisions. Yet, little is known about …
Access to medicines-a systematic review of the literature
N Abbas, SS Hasan, L Curley - Research in Social and Administrative …, 2020 - Elsevier
Background Budgetary constraints and the rising cost of new innovative medicines are the
key challenges for access to medicines. Multiple research studies explored diverse …
key challenges for access to medicines. Multiple research studies explored diverse …